LinkAlpha, a startup developing financial artificial intelligence (AI) agents, recently completed a fundraising round worth 34 billion won, according to venture investment information platform The VC on Wednesday. The investment was co-led by Atinum Investment, U.S. venture capital firm GFT Ventures, and French investment firm AVP. Mirae Asset Venture Investment, Mirae Asset Capital, and East Ventures participated as new investors.
LinkAlpha develops and provides an AI agent platform for institutional investors such as hedge funds, asset managers, and securities firms. The platform supports investment decision-making by integrating and analyzing information scattered across multiple sources—including market data, corporate disclosures, research materials, internal documents, and meeting records—on a single platform. LinkAlpha counts globally renowned institutional investors such as Fidelity, BNP Paribas, and Schonfeld among its clients.
AB180 Secures 21.4 Billion Won in Funding
AB180 has successfully raised 21.4 billion won in investment. With this round, AB180's cumulative funding reached 41.3 billion won. Atinum Investment led the investment, while Z Venture Capital, Korea Development Bank, and IBK Industrial Bank of Korea joined as new investors.
Founded in 2015, AB180 sells global marketing solutions to corporate clients, including its own advertising performance measurement and analysis solution "Airbridge." The company recorded 38.4 billion won in revenue last year and has secured more than 800 corporate clients across some 30 countries, including Korea, Vietnam, and Turkey. AB180 has developed and is testing "Airbridge Go," a next-generation AI marketing agent solution. Airbridge Go is a service in which AI agents autonomously carry out the entire marketing process—from creating ad content, designing and executing campaigns, to optimizing performance—going beyond data analysis and strategy development.
OncoSoft Raises 16 Billion Won
OncoSoft, a company specializing in radiation therapy software, has successfully raised 16 billion won. HB Investment, Devsisters Ventures, and Comes Investment participated in the investment.
Since its founding in 2019, OncoSoft has built the first AI-based full-cycle radiation therapy platform among Korean companies. Its flagship product, the AI contouring (automatic delineation of normal organs and tumors) software "OncoStudio," obtained approval from the Ministry of Food and Drug Safety in February 2022 and is now used for clinical and research purposes at some 50 hospitals and institutions in Korea. The company is steadily improving its AI performance by establishing data cooperation systems with Yonsei Cancer Center, the Mayo Clinic in the U.S., and the University of Chicago in the U.S. Last year, starting with certification from the U.S. Food and Drug Administration (FDA), it obtained medical device certifications in Japan, Singapore, Brazil, and elsewhere, laying the groundwork for overseas market expansion.
